UK markets open in 1 hour
NIKKEI 225
39,496.01 +154.47 (+0.39%) HANG SENG
17,799.31 +82.84 (+0.47%) CRUDE OIL
82.28 +0.54 (+0.66%) GOLD FUTURES
2,336.50 -0.10 (-0.00%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,716.88 +584.91 (+1.22%)
Pharma Mar, S.A. (PHMMF)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 12:16PM EDT
| Previous close | 26.85 |
| Open | 31.15 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 31.15 - 31.15 |
| 52-week range | 26.85 - 46.26 |
| Volume | |
| Avg. volume | 37 |
| Market cap | 544.066M |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 259.58 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.70 (1.98%) |
| Ex-dividend date | 12 Jun 2024 |
| 1y target est | N/A |
- PR Newswire
PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer
PharmaMar (MSE: PHM), world leader in the discovery, development and commercialization of marine-derived cancer treatments, presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States.
© 2024 Yahoo. All rights reserved.